NG
NervGen Pharma Corp. Common stock
NGEN · NASDAQ
$2.19 +0.69% (+$0.02)
1M +25.86%
Market Cap $245.6M
P/E Ratio -
Div. Yield -
ROE 1,156.14%
Bulios Fair Price
$2.04
6.6% downside
Current Price
$2.19
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NGEN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 14.19x
P/FCF N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 36.13%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 74.79%
ROIC 219.93%
Debt
84 /100
Low Current ratio 1.23x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
57 /100
Moderate EPS volatility 42.37%
Profitable years 0
Beta 0.73x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NGEN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adam H. Rogers
Employees
8
Headquarters
West Vancouver
Upcoming events
12 NOV
Earnings
Upcoming earnings report